Insider Brief
- QDX will collaborate with Prelude Therapeutics on finding targets for undisclosed, previously undrugged oncology targets.
- QDX integrates quantum mechanical simulation technology, supercomputing, artificial intelligence and deep drug discovery expertise for computational chemistry and drug discovery.
- Prelude Therapeutics is a clinical-stage precision oncology company.
PRESS RELEASE — — QDX, a computational drug discovery company, announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets.
QDX integrates its world-leading quantum mechanical simulation technology, supercomputing, artificial intelligence, and deep drug discovery expertise to advance computational chemistry and drug discovery.
Peggy Scherle, PhD, CSO of Prelude, commented: “Computational approaches to drug discovery are showing increasing promise. We are pleased to work with the talented team at QDX to leverage their blend of high-performance computing, quantum simulations, and AI on these historically challenging targets.”
Loong Wang, Co-Founder and CEO of QDX, stated: “We are thrilled to be working with the team at Prelude to help break new ground on these programs. This collaboration with Prelude exemplifies the kind of bespoke partnerships that QDX engages in across academia and industry, deploying our best-in-class quantum technology, our massively parallel supercomputing, and AI systems.”
Kelvin Neu, MD, Co-Founder and Chair of QDX, added: “The accomplished biology and chemistry teams at Prelude have been very productive, generating a pipeline of small molecules against important and often challenging oncology targets. QDX has built a powerful platform by thoughtfully integrating complementary disciplines, guided by the practical needs and challenges of novel drug discovery, with a particular focus on select traditionally difficult-to-crack areas. We are honored that Prelude has chosen QDX to support them on these challenging targets and look forward to a productive collaboration.”
